Diabetes is a huge problem affecting 387 million adults by a global prevalence of (8.3%) which is expected to rise to (10.1%) by 2035. Type 2 diabetes, a growing public health problem, is associated with increased morbidity and mortality.
Aim: To evaluate the effects of ginger powder supplementation on glycemic status, lipid profile and beta-cell function in obese Egyptian patients with new-onset type 2 Diabetes Mellitus.
Design: A randomized, single blind, placebo-controlled clinical trial, was performed on 80 subjects newly diagnosed with T2DM conducted at the National Institute of Diabetes and Endocrinology. Subjects were randomly divided into: Group 1: Ginger Group (GG), consumed three capsules daily, each capsule containing: 600-mg of ginger powder (total daily dose was 1.8 g), they also underwent certain diet and physical activity changes, and also received metformin as one 850-mg tablet twice a day with meals for a duration of 8 weeks. Group 2: Placebo Group (PG), which received capsules of the same color, size, and number as (Group 1) but containing wheat flour, they also underwent the same diet, physical activity, and metformin dosage as (Group 1) during the 8 weeks of the study.
Results: Ginger powder supplementation significantly reduced body mass index, fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, total cholesterol, low density lipoprotein cholesterol, triglycerides, fasting insulin levels, and homeostasis model assessment-insulin resistance index(HOMA2-IR). Ginger also significantly increased high density lipoprotein cholesterol levels, beta cell function index (HOMA2-%β) & insulin sensitivity index (HOMA2-%S) in comparison to the placebo group.
Conclusion: Ginger supplementation could be an effective adjuvant therapy for patients with T2DM.
18 - 21 May 2019
European Society of Endocrinology